Advanced recombinant technologies and rapid diagnostic infrastructure.
As the global pharmaceutical landscape shifts toward more personalized and targeted therapies, Monoclonal Antibodies (mAbs) have emerged as the cornerstone of modern medicine. North Macedonia, strategically positioned at the crossroads of Europe and Asia, is rapidly evolving into a specialized hub for biopharmaceutical manufacturing. By leveraging a highly skilled scientific workforce and cost-effective operational environments, North Macedonia provides a compelling alternative to traditional Western European manufacturing sites.
Utilizing high-yield Chinese cell-line technologies integrated with European quality control standards for superior antibody purity.
Direct access to the European Union market via the Balkan corridor, ensuring rapid cold-chain distribution for sensitive biologics.
Adhering to EMA (European Medicines Agency) guidelines and ISO 13485 standards to guarantee reliability and trust.
North Macedonia's pharmaceutical sector is one of the country's most dynamic industries, contributing significantly to its GDP. The government's focus on Technological Industrial Development Zones (TIDZ) has attracted significant investment in high-tech manufacturing. Our facility integrates Hangzhou Jeci Biochem Technology’s R&D prowess with North Macedonia's industrial infrastructure to produce high-affinity monoclonal antibodies.
Current industrial focuses include:
How we are scaling the future of Monoclonal Antibody synthesis.
Our roadmap involves the integration of Artificial Intelligence (AI) in antibody sequence optimization and the adoption of Continuous Manufacturing instead of batch processing. This ensures a "zero-defect" output and minimizes the environmental footprint of our North Macedonia facility. We are also expanding into Bispecific Antibodies (bsAbs) to address complex disease mechanisms.
Located in the heart of China's biotech valley in Hangzhou, Zhejiang Province, Hangzhou Jeci Biochem Technology Co., Ltd. serves as the technological engine for our North Macedonia operations. We specialize in the sales of active pharmaceutical ingredients (APIs), pharmaceutical intermediates, and nutritional products. Our strength lies in our collaborative R&D team, working in depth with elite research institutes and multiple custom processing plants.
Extensive sales channels and long-term relationships with domestic giants, focusing on technology transfer and exclusive agency services.
Established trade relations with India, Southeast Asia, South Korea, Japan, and now expanding heavily into the Balkan and European regions.
From product registration and consulting to sales channel expansion in the complex Chinese and European markets.
Our antibodies and intermediates are essential for:
We assemble and produce larger quantities of intermediates, providing advanced, convenient manufacturing capabilities including batch processing and mass customization. Our production lines are optimized to meet the strict time limits required by global procurement agencies.
Supplying North Macedonia and global markets with high-accuracy rapid tests.
Why Tier-1 pharmaceutical buyers choose North Macedonia-based production.
Procuring monoclonal antibodies on a global scale requires a delicate balance of cost, quality, and regulatory speed. North Macedonia offers a "Nearshoring" advantage for European buyers, reducing lead times from weeks to days. Our localized support team in Skopje provides technical consulting, ensuring that all imported materials and exported biologics comply with both local Macedonian laws and international GMP standards.
We provide exclusive custom manufacturing for pharmaceutical intermediates, tailored to specific molecular requirements.
Consulting services for factory quality management system certification, ensuring your supply chain is audit-ready.
Deep expertise in transferring complex bioprocesses from R&D scale in China to industrial scale in Europe.
Insights from our Senior SEO Growth Director and Technical Team.
A1: North Macedonia offers a unique combination of European regulatory alignment (EMA standards), competitive labor costs, and strategic proximity to major European pharmaceutical hubs. This reduces "Time-to-Market" significantly compared to sourcing from East Asia alone.
A2: We provide detailed characterization data and "Information Gain" via our proprietary tech roadmap, which includes glycan profiling and stability testing data that goes beyond standard industry requirements.
A3: Yes, our collaborative manufacturing plants in North Macedonia and China adhere to strict Good Manufacturing Practices (GMP) and ISO 13485 for medical devices and diagnostic kits.
A4: Absolutely. Our single-use bioreactor technology is specifically designed for high-yield recombinant protein and mAb production, allowing for rapid scale-up of custom molecules.
SJ medical
